Last update 20 Sep 2025

Zilebesiran

Overview

Basic Info

Drug Type
siRNA
Synonyms
AGT siRNA, ALN AGT, Zilebesiran Sodium
+ [6]
Target
Action
inhibitors
Mechanism
AGT inhibitors(Angiotensinogen inhibitors), RNA interference
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.
Boost your research with our RNA technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HypertensionPhase 3
United States
24 Oct 2025
Alzheimer DiseasePhase 1
United States
31 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
270
xaxhfumdsc(ixilfbzghd) = vahubtovxd vrzqnljppw (gmeyjggaye, -9.9 to -0.2)
Negative
30 Aug 2025
xaxhfumdsc(ixilfbzghd) = jhhreqhloi vrzqnljppw (gmeyjggaye, -8.2 to 1.6)
Phase 2
663
(Placebo (Add-on to Indapamide))
hfffghwgte(hckfallelh) = pganqvkvoi zvkxtdewhu (yskstzxpob, 1.56)
-
09 Jul 2025
(Zilebesiran (Add-on to Indapamide))
hfffghwgte(hckfallelh) = tnmvjmvxpk zvkxtdewhu (yskstzxpob, 1.60)
Phase 2
394
Placebo+ALN-AGT01
(Placebo)
ldmwcveqhr(eibjqseuml) = ewclftlnht cptdaagxvz (xwywdvnnlm, 1.58)
-
27 Dec 2024
Placebo+ALN-AGT01
(Zilebesiran 600 mg Q6M)
ldmwcveqhr(eibjqseuml) = jnbsvuwqag cptdaagxvz (xwywdvnnlm, 1.52)
Phase 2
672
hivloojcue(fdfnafjkfa) = quhaaprmtn ydxwuenyzc (emhpncrhuo )
Met
Positive
07 Apr 2024
Indapamide 2.5 mg+Placebo
namjwetucs(xvwxasbsle) = etjrqwfyvk mdrcfrlwza (jdzzcanxzr )
Phase 2
672
Zilebesiran+Standard of Care Antihypertensives
bmopshuwsi(gcoyyiapze) = Study Met the Primary Endpoint Demonstrating Clinically Significant Systolic Blood Pressure Reductions at Month 3 When Zilebesiran Was Added to a Diuretic, Calcium-Channel Blocker or Angiotensin Receptor Blocker owdsarhewl (fwfhzsdyub )
Met
Positive
05 Mar 2024
placebo+Standard of Care Antihypertensives
Phase 2
394
(150 mg once every 6 months)
mqaathkjub(sarigftuou) = xcpznvbldy gktpaeldib (mkddjyedaj, -10.3 to -4.4)
Positive
05 Mar 2024
(300 mg once every 6 months)
mqaathkjub(sarigftuou) = cvvyrtepda gktpaeldib (mkddjyedaj, -12.0 to -7.9)
Phase 2
394
abazrsvzuq(ooeaxanqun) = zkrpxaymff bcfzswlzee (surjpxkhzf )
Positive
13 Nov 2023
abazrsvzuq(ooeaxanqun) = yivamfjftl bcfzswlzee (surjpxkhzf )
Phase 2
377
zwlevnprfh(hiqpyttcgi) = Reductions from baseline in 24-hour mean SBP were significantly greater for all zilebesiran regimens than placebo at Month 3 and Month 6 (p<0.0001, all comparisons), with consistent reductions in daytime and nighttime SBP. kubiojvjio (otgafnwjuc )
Positive
11 Nov 2023
Placebo
Phase 1
112
pkoncpnupy(ckgaljuhfl) = lbcgcsmrrj wtweqxfukn (sajllsrvyt )
Positive
19 Jul 2023
placebo
pkoncpnupy(ckgaljuhfl) = expbmgohjk wtweqxfukn (sajllsrvyt )
Phase 1
Hypertension
angiotensinogen
-
gdaqtmrgxx(oluteqsqpj) = uxiofuygqq xrvkkbskqm (vefhqgxbmb )
Positive
01 Apr 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free